Yunnan’s Pharmaceutical Firms Eye Medical Cosmetics
This article was originally published in PharmAsia News
Executive Summary
Yunnan province's three leading pharmaceutical companies Yunnan Baiyao, Kunming Shenghuo Pharmaceutical and Kunming Dihon Pharmaceutical are focusing on developing medical cosmetics as a new source of expansion. Shenghuo, aiming to be China's top medical cosmetic brand, will launch four new products this October. Dihon has established a daily chemical branch in Shanghai and launched Dianhong Skin Moisturizer in early 2008. Its chemical product Dianhong Kangwang is projected to hit RMB 200 million ($29.2 million) in revenue this year. Yunnan Baiyao is expected to officially launch its first medical cosmetic product in 2009. Experts observe that local pharmaceutical firms are actively seeking breakthroughs in the tough times. Their inherent strengths in developing medical cosmetic products will provide them leverage for entering the promising industry. (Click here for more - Chinese Language)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.